Pharmaceutical

Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma out-licensed another immun...

The University of Michigan is suing AstraZeneca over claims that the British drugmaker continues to market and sell FluMist despite not renewing a key...

Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to...

Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amy...

Flying high after an FDA approval four months ago to treat generalized myasthenia gravis, Johnson & Johnson’s much-touted Imaavy has taken a hit, comi...

Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challeng...

Wegovy's mechanism of action could be ideal for patients with more moderate disease, according to gastroenterologists and hepatologists surveyed by Sp...

The FDA has approved a once-weekly subcutaneous maintenance dose of Leqembi in an autoinjector, dubbed Leqembi IQLIK, which Eisai has hailed as a key...

While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion, another of the biotech’s BTK i...

Fresenius and Charles River Laboratories are among 18 partners that have formed a European Union-supported consortium to develop an automated, hospita...